Skip to content

Efficacy and Safety of Individualized Sodium Dialysis in Maintenance Hemodialysis Patients With Resistant Hypertension: a Cross-over Randomized Controlled Trial.

Efficacy and Safety of Individualized Sodium Dialysis in Maintenance Hemodialysis Patients With Resistant Hypertension: a Cross-over Randomized Controlled Trial.

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027405
Enrollment
Unknown
Registered
2019-11-12
Start date
2019-11-13
Completion date
Unknown
Last updated
2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory hypertension

Interventions

Group A:Phase I: Low-sodium dialysis combined with antihypertensive therapy
phase II: Standard sodium dialysis combined with antihypertensive therapy.
Group B:phase I: Standard sodium dialysis combined with antihypertensive therapy
Phase II: Low-sodium dialysis combined with antihypertensive therapy.

Sponsors

The Eighth Affiliated Hospital, Sun Yat-Sen University (Shenzhen Futian)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. understand and have signed the informed consent; 2. diagnosis as chronic renal failure and have undergone maintenance hemodialysis for more than 1 year, aged >30 years, with hypertension; 3. with optimal or best-tolerated doses of three or more antihypertensive drugs, pressure fails to lower office < 140/90mmHg; 4. no cardiovascular and cerebrovascular events in four weeks; 5. can swallow pills and receive subcutaneous injections; 6. negative pregnancy test and willing to contraception during treatment.

Exclusion criteria

Exclusion criteria: 1. pregnancy, breastfeeding or malignant tumor; 2. do not reach the ideal dry weight or blood pressure is unstable; 3. hypotension; 4. with acute heart failure or arrhythmia; 5. no legal capacity or legal capacity is restricted; 6. disagree for the participation from researchers; 7. severe heart, liver or lung dysfunction; 8. poor adherence.

Design outcomes

Primary

MeasureTime frame
Systolic pressure;Diastolic pressure;

Secondary

MeasureTime frame
Electrocardiogram;Echocardiography;Blood routine;Liver function;Renal function;

Countries

China

Contacts

Public ContactHuang Hui

The Eighth Affiliated Hospital, Sun Yat-Sen University (Shenzhen Futian)

huanghui765@hotmail.com+86 13923730765

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026